{"id":499077,"date":"2021-05-26T09:33:19","date_gmt":"2021-05-26T13:33:19","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/pavmed-subsidiary-lucid-diagnostics-receives-ce-mark-certification-for-its-esocheck-esophageal-cell-collection-device\/"},"modified":"2021-05-26T09:33:19","modified_gmt":"2021-05-26T13:33:19","slug":"pavmed-subsidiary-lucid-diagnostics-receives-ce-mark-certification-for-its-esocheck-esophageal-cell-collection-device","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/pavmed-subsidiary-lucid-diagnostics-receives-ce-mark-certification-for-its-esocheck-esophageal-cell-collection-device\/","title":{"rendered":"PAVmed Subsidiary Lucid Diagnostics Receives CE Mark Certification for its EsoCheck\u00ae Esophageal Cell Collection Device"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">NEW YORK, May  26, 2021  (GLOBE NEWSWIRE) &#8212; <strong>PAVmed Inc. (Nasdaq: PAVM, PAVMZ<\/strong>) (\u201cPAVmed\u201d), a highly differentiated, multi-product, commercial-stage medical device company, and its major subsidiary Lucid Diagnostics Inc. (\u201cLucid\u201d), today announced that Lucid\u2019s EsoCheck<sup>\u00ae<\/sup> Esophageal Cell Collection Device with Collect+Protect<sup>\u2122<\/sup> technology (\u201cEsoCheck\u201d) has received CE Mark certification.<\/p>\n<p align=\"justify\">EU-based Notified Body T\u00dcV Rhineland LGA Products GMBH issued a CE Certificate, effective May 24, 2021, declaring that EsoCheck conforms to the essential requirements of Medical Device Directive 93\/42\/EEC. With CE Mark secured, EsoCheck may now be marketed in CE Mark European countries, which include the European Economic Area (the EU, Norway, Iceland, and Lichtenstein), Switzerland, and, until July 1, 2023, the United Kingdom.<\/p>\n<p align=\"justify\">EsoCheck is an FDA-cleared swallowable balloon capsule catheter, which allows a clinician to sample surface cells from the esophagus in a less than 5-minute non-invasive office procedure, the only such device capable of doing so in an anatomically targeted fashion, without sample dilution or contamination (<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=9Gx-4YfOP9LrkKcQi_qTTKpBLFKn-MTUTRvNmWRQkVzGNx3muKmar5WPCCH8mLb-r8wFIsY-4vRQ4LXaAcYexNZxn1IJe15Q4RWDJSgpnwWR10HuYunuLEWXCNhC2b4e\" rel=\"nofollow noopener\" target=\"_blank\">EsoCheck animation<\/a>). EsoCheck, paired with Lucid\u2019s EsoGuard<sup>\u00ae<\/sup> Esophageal DNA Test (\u201cEsoGuard\u201d), are the first and only commercially available diagnostic technologies capable of serving as a widespread screening tool to prevent deaths through the early detection of esophageal precancer and cancer in at-risk chronic heartburn patients. As a \u201cGeneral IVD\u201d under Europe\u2019s In-Vitro Diagnostic Medical Devices Directive 98\/79\/EC, EsoGuard only requires self-certification, which Lucid and its authorized representative expect to complete in the very near future.<\/p>\n<p align=\"justify\">\u201cChronic heartburn is as ubiquitous, and esophageal cancer as deadly, in Europe as it is in the U.S. so this certification represents yet another important milestone in our mission to prevent deaths through the early detection of esophageal precancer and cancer,\u201d said Lishan Aklog, M.D., PAVmed\u2019s Chairman and Chief Executive Officer, and Lucid\u2019s Executive Chairman. \u201cLucid has already developed strong relationships with European key opinion leaders in esophageal disease who are participating in our pivotal clinical trials. We look forward to leveraging these relationships and proceeding with a commercial launch in select European countries in the near future.\u201d<\/p>\n<p align=\"justify\">\n        <strong>About PAVmed<\/strong><br \/>\n        <strong> and Lucid<\/strong>\n      <\/p>\n<p align=\"justify\">PAVmed Inc. is a highly differentiated, multi-product, commercial-stage medical technology company with a diversified product pipeline addressing unmet clinical needs encompassing a broad spectrum of clinical areas with attractive regulatory pathways and market opportunities. Its major subsidiary, Lucid Diagnostics Inc., markets the first and only commercial tools for widespread early detection of esophageal precancer and cancer \u2013 the EsoGuard<sup>\u00ae<\/sup> Esophageal DNA Test and EsoCheck<sup>\u00ae<\/sup> Esophageal Cell Collection Device. Its GI Health division also includes the complementary EsoCure<sup>\u2122<\/sup> Esophageal Ablation Device with Caldus<sup>\u2122<\/sup> Technology. Its Minimally Invasive Interventions markets its CarpX<sup>\u00ae<\/sup> Minimally Invasive Device for Carpal Tunnel Syndrome. Other divisions include Infusion Therapy (PortIO<sup>\u2122<\/sup> Implantable Intraosseous Vascular Access Device and NextFlo<sup>\u2122<\/sup> Intravenous Infusion Set), and Emerging Innovations (non-invasive laser-based glucose monitoring, pediatric ear tubes, and mechanical circulatory support). For more information, please visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=UBaEjb5WB0L55ZDLaNGKCEejV_y0Jy4Wk02mBWSKAup-mn-_38DPOkmsSt8XxFdCtwnz-n_vJVTAvRy9-RfvNg==\" rel=\"nofollow noopener\" target=\"_blank\">www.pavmed.com<\/a>, follow us on <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=fGlRgms7EdygqtOUBvyKC25Gr_l3q0U9Szzl1auBZS2ZqlEebuIiesdyMUPE6jaYSdHEXOZ3JDKviPrzZlJJHA==\" rel=\"nofollow noopener\" target=\"_blank\">Twitter<\/a>, connect with us on <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=PWUh-vbxL8ygLOx8L879PCX7_xVmDvYyMDtbfA3UpDdZtLVE-hr3ZUM6HV-0oNs393s5p3Tt7DXtpYqMfdHGOEGo2HoT5tz_n34GoYaP6ZE=\" rel=\"nofollow noopener\" target=\"_blank\">LinkedIn<\/a>, and watch our videos on <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=j0cAFXWvLgBP6I55nbrGCHwbimPCfYSsDj2n3Zo-rnAMFq_CmxCZNEYyCMcnzZiNmjlm9-KVw_JPSXlQzuMSun-GCYZ8AycID5zb4eUf9i24fFN8y6kF8do1DWSAGf0-\" rel=\"nofollow noopener\" target=\"_blank\">YouTube<\/a>. For more information on our majority owned subsidiary, Lucid Diagnostics Inc., please visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=a4PUsBO2JtAFCVJijJjVPUMcBUTi3_RpgEQZXuCllfJZXQ0eeilOUx-cukE_mom47UHghbrENkh9nzD_mQqHEg==\" rel=\"nofollow noopener\" target=\"_blank\">www.luciddx.com<\/a>, follow Lucid on <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=fGlRgms7EdygqtOUBvyKC59YBGQDKGgoYFOmCIOd0618hOiGs6nv6fAvEpEwTZ37xBShgBq2jjvNQDYk-_Q8lA==\" rel=\"nofollow noopener\" target=\"_blank\">Twitter<\/a>, and connect with Lucid on <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=PWUh-vbxL8ygLOx8L879PJQUZvQQXuvbEpQATKGTbB9dYIpZemmQJD04f4MU2isJxL-TuQTRiqPPtBi7DKwtbfKy90xCUdPNiXblrzkYSzU=\" rel=\"nofollow noopener\" target=\"_blank\">LinkedIn<\/a>. For detailed information on EsoGuard, please visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=A7i_IXz1np-jhXlV9cNh2y0zqYdYyllC44IHB-keJ4-x0cJo8r3jl_C_u2_NplAmqRi8ZLfcmY1vWctLcvk4_g==\" rel=\"nofollow noopener\" target=\"_blank\">www.EsoGuard.com<\/a> and follow us on <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=fGlRgms7EdygqtOUBvyKC9Lu47ugG9x1d1jbO635-qRWRCCxA5R46f8a5PhfnGopx4TWogoHRTBSSokdSJU4tQ==\" rel=\"nofollow noopener\" target=\"_blank\">Twitter<\/a>, <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=AdzIK8sssaKw4srVIR-K9J7w3uizoql9_GdFSQ-rsIl1XG3GfZxLkyZj8IH8Tobkvm7-tBBiKqxa6WIjBDKWZA==\" rel=\"nofollow noopener\" target=\"_blank\">Facebook<\/a> and <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=u5DGXmXx_OkH4zIYCYwmMCGqqaUl7elasbr_HqKCqLd7zuKaIiLPlbs7ZDtIiZPztc55krmvKJr6Pw2MiLT06KKGpdPLLxv0XqUyX20pPgg=\" rel=\"nofollow noopener\" target=\"_blank\">Instagram<\/a>.<\/p>\n<p align=\"justify\">\n        <strong>Forward-Looking Statements<\/strong>\n      <\/p>\n<p align=\"justify\">This press release includes forward-looking statements that involve risks and uncertainties. Forward-looking statements are statements that are not historical facts. Such forward-looking statements, based upon the current beliefs and expectations of PAVmed\u2019s management, are subject to risks and uncertainties, which could cause actual results to differ from the forward-looking statements. Risks and uncertainties that may cause such differences include, among other things, volatility in the price of PAVmed\u2019s common stock, Series W Warrants and Series Z Warrants; general economic and market conditions; the uncertainties inherent in research and development, including the cost and time required advance PAVmed\u2019s products to regulatory submission; whether regulatory authorities will be satisfied with the design of and results from PAVmed\u2019s preclinical studies; whether and when PAVmed\u2019s products are cleared by regulatory authorities; market acceptance of PAVmed\u2019s products once cleared and commercialized; our ability to raise additional funding and other competitive developments. PAVmed has not yet received clearance from the FDA or other regulatory body to market many of its products. The Company has been monitoring the COVID-19 pandemic and its impact on our business. The Company expects the significance of the COVID-19 pandemic, including the extent of its effect on the Company\u2019s financial and operational results, to be dictated by, among other things, the success of efforts to contain it and the impact of actions taken in response. New risks and uncertainties may arise from time to time and are difficult to predict. All of these factors are difficult or impossible to predict accurately and many of them are beyond PAVmed\u2019s control. For a further list and description of these and other important risks and uncertainties that may affect PAVmed\u2019s future operations, see Part I, Item IA, \u201cRisk Factors,\u201d in PAVmed\u2019s most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, as the same may be updated in Part II, Item 1A, \u201cRisk Factors\u201d in any Quarterly Report on Form 10-Q filed by PAVmed after its most recent Annual Report. PAVmed disclaims any intention or obligation to publicly update or revise any forward-looking statement to reflect any change in its expectations or in events, conditions, or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements.<\/p>\n<p align=\"justify\">\n        <strong>Contacts:<\/strong>\n      <\/p>\n<p align=\"justify\">\n        <u>Investors<\/u><br \/>\n        <br \/>Mike Havrilla<br \/>Director of Investor Relations<br \/>(814) 241-4138<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=e3t7TecfIyd3jFkfiWdbhL7j1fTPmE7KY20dn_t0AK4GwwDElZ2qxEGR52uEkPjLmeq9FjuJvXLb5GxYjm3c8Q==\" rel=\"nofollow noopener\" target=\"_blank\">JMH@PAVmed.com<\/a><\/p>\n<p align=\"justify\">\n        <u>Media<\/u><br \/>\n        <br \/>Shaun O\u2019Neil<br \/>Chief Commercial Officer<br \/>(518) 812-3087<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=_iyIB1u3UUmPwZMtsHV9wokNwdcIaPQ9epd8o-GS-FwnIKzYlGIjgfCwOGHkPE21892ymTO__tqEVljC5q7ZwQ==\" rel=\"nofollow noopener\" target=\"_blank\">SMO@PAVmed.com<\/a><\/p>\n<p>Jim Heins \/ Katie Gallagher<br \/>LaVoieHealthScience<br \/>(646) 491-7042 \/ (617) 792-3937<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=2OHjHZxwYo3SYHv6xTJ4qguGdS9JW_wX4DPOiaOy11VRGE1aEdZ1QMX1W-_Fo5zgoXoA8pyMiFgqy3uNP4XgKSpDW7HdQaC57IHUof6aq2KTGDNrioLBvX2hRdWQ-EaM\" rel=\"nofollow noopener\" target=\"_blank\">PAVmed@lavoiehealthscience.com<\/a><\/p>\n<p \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI0MzI5MiM0MjAyNTUxIzUwMDA0OTg1OA==\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/e1097cb7-b52c-456b-bcdc-f345d822de33\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>NEW YORK, May 26, 2021 (GLOBE NEWSWIRE) &#8212; PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (\u201cPAVmed\u201d), a highly differentiated, multi-product, commercial-stage medical device company, and its major subsidiary Lucid Diagnostics Inc. (\u201cLucid\u201d), today announced that Lucid\u2019s EsoCheck\u00ae Esophageal Cell Collection Device with Collect+Protect\u2122 technology (\u201cEsoCheck\u201d) has received CE Mark certification. EU-based Notified Body T\u00dcV Rhineland LGA Products GMBH issued a CE Certificate, effective May 24, 2021, declaring that EsoCheck conforms to the essential requirements of Medical Device Directive 93\/42\/EEC. With CE Mark secured, EsoCheck may now be marketed in CE Mark European countries, which include the European Economic Area (the EU, Norway, Iceland, and Lichtenstein), Switzerland, and, until July 1, 2023, the United Kingdom. EsoCheck is an FDA-cleared swallowable balloon capsule catheter, &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/pavmed-subsidiary-lucid-diagnostics-receives-ce-mark-certification-for-its-esocheck-esophageal-cell-collection-device\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;PAVmed Subsidiary Lucid Diagnostics Receives CE Mark Certification for its EsoCheck\u00ae Esophageal Cell Collection Device&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-499077","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>PAVmed Subsidiary Lucid Diagnostics Receives CE Mark Certification for its EsoCheck\u00ae Esophageal Cell Collection Device - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/pavmed-subsidiary-lucid-diagnostics-receives-ce-mark-certification-for-its-esocheck-esophageal-cell-collection-device\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"PAVmed Subsidiary Lucid Diagnostics Receives CE Mark Certification for its EsoCheck\u00ae Esophageal Cell Collection Device - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"NEW YORK, May 26, 2021 (GLOBE NEWSWIRE) &#8212; PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (\u201cPAVmed\u201d), a highly differentiated, multi-product, commercial-stage medical device company, and its major subsidiary Lucid Diagnostics Inc. (\u201cLucid\u201d), today announced that Lucid\u2019s EsoCheck\u00ae Esophageal Cell Collection Device with Collect+Protect\u2122 technology (\u201cEsoCheck\u201d) has received CE Mark certification. EU-based Notified Body T\u00dcV Rhineland LGA Products GMBH issued a CE Certificate, effective May 24, 2021, declaring that EsoCheck conforms to the essential requirements of Medical Device Directive 93\/42\/EEC. With CE Mark secured, EsoCheck may now be marketed in CE Mark European countries, which include the European Economic Area (the EU, Norway, Iceland, and Lichtenstein), Switzerland, and, until July 1, 2023, the United Kingdom. EsoCheck is an FDA-cleared swallowable balloon capsule catheter, &hellip; Continue reading &quot;PAVmed Subsidiary Lucid Diagnostics Receives CE Mark Certification for its EsoCheck\u00ae Esophageal Cell Collection Device&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/pavmed-subsidiary-lucid-diagnostics-receives-ce-mark-certification-for-its-esocheck-esophageal-cell-collection-device\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-05-26T13:33:19+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI0MzI5MiM0MjAyNTUxIzUwMDA0OTg1OA==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pavmed-subsidiary-lucid-diagnostics-receives-ce-mark-certification-for-its-esocheck-esophageal-cell-collection-device\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pavmed-subsidiary-lucid-diagnostics-receives-ce-mark-certification-for-its-esocheck-esophageal-cell-collection-device\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"PAVmed Subsidiary Lucid Diagnostics Receives CE Mark Certification for its EsoCheck\u00ae Esophageal Cell Collection Device\",\"datePublished\":\"2021-05-26T13:33:19+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pavmed-subsidiary-lucid-diagnostics-receives-ce-mark-certification-for-its-esocheck-esophageal-cell-collection-device\\\/\"},\"wordCount\":968,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pavmed-subsidiary-lucid-diagnostics-receives-ce-mark-certification-for-its-esocheck-esophageal-cell-collection-device\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI0MzI5MiM0MjAyNTUxIzUwMDA0OTg1OA==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pavmed-subsidiary-lucid-diagnostics-receives-ce-mark-certification-for-its-esocheck-esophageal-cell-collection-device\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pavmed-subsidiary-lucid-diagnostics-receives-ce-mark-certification-for-its-esocheck-esophageal-cell-collection-device\\\/\",\"name\":\"PAVmed Subsidiary Lucid Diagnostics Receives CE Mark Certification for its EsoCheck\u00ae Esophageal Cell Collection Device - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pavmed-subsidiary-lucid-diagnostics-receives-ce-mark-certification-for-its-esocheck-esophageal-cell-collection-device\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pavmed-subsidiary-lucid-diagnostics-receives-ce-mark-certification-for-its-esocheck-esophageal-cell-collection-device\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI0MzI5MiM0MjAyNTUxIzUwMDA0OTg1OA==\",\"datePublished\":\"2021-05-26T13:33:19+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pavmed-subsidiary-lucid-diagnostics-receives-ce-mark-certification-for-its-esocheck-esophageal-cell-collection-device\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pavmed-subsidiary-lucid-diagnostics-receives-ce-mark-certification-for-its-esocheck-esophageal-cell-collection-device\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pavmed-subsidiary-lucid-diagnostics-receives-ce-mark-certification-for-its-esocheck-esophageal-cell-collection-device\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI0MzI5MiM0MjAyNTUxIzUwMDA0OTg1OA==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI0MzI5MiM0MjAyNTUxIzUwMDA0OTg1OA==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pavmed-subsidiary-lucid-diagnostics-receives-ce-mark-certification-for-its-esocheck-esophageal-cell-collection-device\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"PAVmed Subsidiary Lucid Diagnostics Receives CE Mark Certification for its EsoCheck\u00ae Esophageal Cell Collection Device\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"PAVmed Subsidiary Lucid Diagnostics Receives CE Mark Certification for its EsoCheck\u00ae Esophageal Cell Collection Device - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/pavmed-subsidiary-lucid-diagnostics-receives-ce-mark-certification-for-its-esocheck-esophageal-cell-collection-device\/","og_locale":"en_US","og_type":"article","og_title":"PAVmed Subsidiary Lucid Diagnostics Receives CE Mark Certification for its EsoCheck\u00ae Esophageal Cell Collection Device - Market Newsdesk","og_description":"NEW YORK, May 26, 2021 (GLOBE NEWSWIRE) &#8212; PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (\u201cPAVmed\u201d), a highly differentiated, multi-product, commercial-stage medical device company, and its major subsidiary Lucid Diagnostics Inc. (\u201cLucid\u201d), today announced that Lucid\u2019s EsoCheck\u00ae Esophageal Cell Collection Device with Collect+Protect\u2122 technology (\u201cEsoCheck\u201d) has received CE Mark certification. EU-based Notified Body T\u00dcV Rhineland LGA Products GMBH issued a CE Certificate, effective May 24, 2021, declaring that EsoCheck conforms to the essential requirements of Medical Device Directive 93\/42\/EEC. With CE Mark secured, EsoCheck may now be marketed in CE Mark European countries, which include the European Economic Area (the EU, Norway, Iceland, and Lichtenstein), Switzerland, and, until July 1, 2023, the United Kingdom. EsoCheck is an FDA-cleared swallowable balloon capsule catheter, &hellip; Continue reading \"PAVmed Subsidiary Lucid Diagnostics Receives CE Mark Certification for its EsoCheck\u00ae Esophageal Cell Collection Device\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/pavmed-subsidiary-lucid-diagnostics-receives-ce-mark-certification-for-its-esocheck-esophageal-cell-collection-device\/","og_site_name":"Market Newsdesk","article_published_time":"2021-05-26T13:33:19+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI0MzI5MiM0MjAyNTUxIzUwMDA0OTg1OA==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pavmed-subsidiary-lucid-diagnostics-receives-ce-mark-certification-for-its-esocheck-esophageal-cell-collection-device\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pavmed-subsidiary-lucid-diagnostics-receives-ce-mark-certification-for-its-esocheck-esophageal-cell-collection-device\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"PAVmed Subsidiary Lucid Diagnostics Receives CE Mark Certification for its EsoCheck\u00ae Esophageal Cell Collection Device","datePublished":"2021-05-26T13:33:19+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pavmed-subsidiary-lucid-diagnostics-receives-ce-mark-certification-for-its-esocheck-esophageal-cell-collection-device\/"},"wordCount":968,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pavmed-subsidiary-lucid-diagnostics-receives-ce-mark-certification-for-its-esocheck-esophageal-cell-collection-device\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI0MzI5MiM0MjAyNTUxIzUwMDA0OTg1OA==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pavmed-subsidiary-lucid-diagnostics-receives-ce-mark-certification-for-its-esocheck-esophageal-cell-collection-device\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/pavmed-subsidiary-lucid-diagnostics-receives-ce-mark-certification-for-its-esocheck-esophageal-cell-collection-device\/","name":"PAVmed Subsidiary Lucid Diagnostics Receives CE Mark Certification for its EsoCheck\u00ae Esophageal Cell Collection Device - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pavmed-subsidiary-lucid-diagnostics-receives-ce-mark-certification-for-its-esocheck-esophageal-cell-collection-device\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pavmed-subsidiary-lucid-diagnostics-receives-ce-mark-certification-for-its-esocheck-esophageal-cell-collection-device\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI0MzI5MiM0MjAyNTUxIzUwMDA0OTg1OA==","datePublished":"2021-05-26T13:33:19+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pavmed-subsidiary-lucid-diagnostics-receives-ce-mark-certification-for-its-esocheck-esophageal-cell-collection-device\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/pavmed-subsidiary-lucid-diagnostics-receives-ce-mark-certification-for-its-esocheck-esophageal-cell-collection-device\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pavmed-subsidiary-lucid-diagnostics-receives-ce-mark-certification-for-its-esocheck-esophageal-cell-collection-device\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI0MzI5MiM0MjAyNTUxIzUwMDA0OTg1OA==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI0MzI5MiM0MjAyNTUxIzUwMDA0OTg1OA=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pavmed-subsidiary-lucid-diagnostics-receives-ce-mark-certification-for-its-esocheck-esophageal-cell-collection-device\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"PAVmed Subsidiary Lucid Diagnostics Receives CE Mark Certification for its EsoCheck\u00ae Esophageal Cell Collection Device"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/499077","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=499077"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/499077\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=499077"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=499077"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=499077"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}